Active Ingredient: Adalimumab
Adalimumab is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
20 - 40 mg
From 20 To 40 mg once every 14 day(s)
The recommended dose of adalimumab for patients with enthesitis-related arthritis from 6 years of age is based on body weight (Table). Adalimumab is administered every other week via subcutaneous injection.
Adalimumab Dose for Patients with Enthesitis-Related Arthritis:
| Patient Weight | Dosing Regimen |
|---|---|
| 15 kg to <30 kg | 20 mg every other week |
| ≥30 kg | 40 mg every other week |
Adalimumab has not been studied in patients with enthesitis-related arthritis aged less than 6 years.
Adalimumab may be available in other strengths and/or presentations depending on the individual treatment needs.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
